206 related articles for article (PubMed ID: 23456571)
1. CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis.
Gui JC; Yan WL; Liu XD
Clin Exp Med; 2014 May; 14(2):225-33. PubMed ID: 23456571
[TBL] [Abstract][Full Text] [Related]
2. Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis.
Zhang Y; Yang J; Li H; Wu Y; Zhang H; Chen W
Int J Clin Exp Med; 2015; 8(7):11683-91. PubMed ID: 26380005
[TBL] [Abstract][Full Text] [Related]
3. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
4. Serum carbohydrate antigen 242 expression exerts crucial function in the diagnosis of pancreatic cancer.
Li X; Guo X; Li H; Lin H; Sun Y
Tumour Biol; 2014 Jun; 35(6):5281-6. PubMed ID: 24510349
[TBL] [Abstract][Full Text] [Related]
5. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
6. Behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer.
Banfi G; Zerbi A; Pastori S; Parolini D; Di Carlo V; Bonini P
Clin Chem; 1993 Mar; 39(3):420-3. PubMed ID: 8448851
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer.
Kawa S; Tokoo M; Hasebe O; Hayashi K; Imai H; Oguchi H; Kiyosawa K; Furuta S; Homma T
Br J Cancer; 1994 Sep; 70(3):481-6. PubMed ID: 8080734
[TBL] [Abstract][Full Text] [Related]
8. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
9. Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer.
Jiang JT; Wu CP; Deng HF; Lu MY; Wu J; Zhang HY; Sun WH; Ji M
World J Gastroenterol; 2004 Jun; 10(11):1675-7. PubMed ID: 15162550
[TBL] [Abstract][Full Text] [Related]
10. Carbohydrate antigen 242 highly consists with carbohydrate antigen 19-9 in diagnosis and prognosis of colorectal cancer: study on 185 cases.
Yang XQ; Chen C; Peng CW; Liu SP; Li Y
Med Oncol; 2012 Jun; 29(2):1030-6. PubMed ID: 21553105
[TBL] [Abstract][Full Text] [Related]
11. CA 19.9, CA 242 and CEA in the diagnosis and follow-up of pancreatic cancer.
Banfi G; Bravi S; Ardemagni A; Zerbi A
Int J Biol Markers; 1996; 11(2):77-81. PubMed ID: 8776607
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis.
Huang Z; Liu F
Tumour Biol; 2014 Aug; 35(8):7459-65. PubMed ID: 24789274
[TBL] [Abstract][Full Text] [Related]
14. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
[TBL] [Abstract][Full Text] [Related]
15. [The diagnostic value of serum carcinoma markers, fecal K-ras and p53 gene mutation in pancreatic cancers].
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Zhonghua Nei Ke Za Zhi; 2005 Oct; 44(10):741-4. PubMed ID: 16255879
[TBL] [Abstract][Full Text] [Related]
16. Application values of detection of serum CA199, CA242 and CA50 in the diagnosis of pancreatic cancer.
Lei XF; Jia SZ; Ye J; Qiao YL; Zhao GM; Li XH; Chang H
J Biol Regul Homeost Agents; 2017; 31(2):383-388. PubMed ID: 28685541
[TBL] [Abstract][Full Text] [Related]
17. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer.
Jing JX; Wang Y; Xu XQ; Sun T; Tian BG; Du LL; Zhao XW; Han CZ
Asian Pac J Cancer Prev; 2014; 15(23):10267-72. PubMed ID: 25556459
[TBL] [Abstract][Full Text] [Related]
18. Macrophage inhibitory cytokine-1 versus carbohydrate antigen 19-9 as a biomarker for diagnosis of pancreatic cancer: A PRISMA-compliant meta-analysis of diagnostic accuracy studies.
Yang Y; Yan S; Tian H; Bao Y
Medicine (Baltimore); 2018 Mar; 97(9):e9994. PubMed ID: 29489701
[TBL] [Abstract][Full Text] [Related]
19. Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy.
Ge L; Pan B; Song F; Ma J; Zeraatkar D; Zhou J; Tian J
BMJ Open; 2017 Dec; 7(12):e018175. PubMed ID: 29282264
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of diagnostic value of serum Carbohydrate antigen 199 in pancreatic cancer.
Zhang Y; Jiang L; Song L
Minerva Med; 2016 Feb; 107(1):62-9. PubMed ID: 26824636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]